Hanmi Pharmaceutical Company Limited
PharmaSeoul, South Korea, South Korea · Est. 1983 · 1,200 employees
Hanmi Pharmaceutical is a South Korean biopharmaceutical company focused on developing novel drug candidates in oncology and other therapeutic areas.
10
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
7
Indications↗
Distinct diseases across all programs
190
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
10 drugs in development
Phase 31
Phase 23
Phase 16
By Therapeutic Area
top 3
Oncology
330%
Metabolic & Endocrine
220%
Gastroenterology
110%
R&D Momentum
50/100
Pipeline Velocity
30/100
Trial Completion Rate
97/100
Pipeline Concentration
30/100
Pipeline Freshness
28/100
Strategic Signals
- ↗Early-stage heavy pipeline may seek late-stage partners
- ↗Active in Metabolic & Endocrine but thin pipeline — potential licensing opportunity
Activity
Key Events
Sep 1, 2026TrialA Multicenter, Randomized, Double-blind, Phase III Study to Evaluate Efficacy and Safety of HGP2304 in Patients With Essential Hypertension
Aug 27, 2026TrialA Phase 2, Multiple Ascending Dose, Open-label, Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)
Aug 26, 2026TrialA Multicenter, Prospective, Non-interventional, Observational Study to Evaluate Effectiveness and Safety of Sequential Triple Combination Therapy (Amlodipine/Losartan/Chlorthalidone) in Korean Patients With Hypertension
Aug 20, 2026TrialA Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
Aug 18, 2026TrialA Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate Efficacy, Safety, and Tolerability of HM15275 for 36 Weeks in Subjects With Type 2 Diabetes Mellitus
Aug 13, 2026TrialA Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study of HM97662 as a Single Agent in Patients With Advanced or Metastatic Solid Tumors
Aug 13, 2026TrialA Phase I, Open-Label, Multinational, Multicenter, Dose Escalation and Expansion Study of BH3120, as a Single Agent and in Combination With Pembrolizumab, in Patients With Advanced or Metastatic Solid Tumors
Aug 13, 2026TrialA Multicenter, Proof-of-concept, Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15912 (Sonefpeglutide) in Adult Subjects With Short Bowel Syndrome-associated Intestinal Failure (SBS-IF)
4 more events
Jul 8, 2026TrialA Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus
Jul 1, 2026TrialA Multicenter, Randomized, Double-blind, Phase III Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension
Feb 12, 2026TrialBelvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma
Feb 1, 2026TrialA Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
Details
Company Info
Company Overview
—
Mkt Cap
$500.0M
Revenue
—
Cash
CEOJae-Ho Choi
Founded1983
Employees1,200
HQSeoul, South Korea, South Korea
Websitehanmipharm.com
LinkedInCompany Page
Therapeutic Focus
OncologyCardiovascularImmunologyNeurology
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Gastroenterology
Gastroenterology
Metabolic & Endocrine
Unknown / Other
Single Ascending Dose
HM17321Phase 1
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)